t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumab
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06282-5 ↗Kurz gefasst
Fallbericht in der Zeitschrift Annals of Hematology, 2025. Verfasst von Julia T Geyer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 22, Immunoglobulin Heavy Chains. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Translocations involving immunoglobin (IG) are common in B-cell neoplasms. These IG translocations lead to the disposition of the enhancer or promoter of an IG locus, typically IGH, to a proto-oncogene, resulting in the elevated expression of the cancer gene. IG fusions play an important role in the diagnosis, prognostication, and therapy selection of B-cell lymphomas. A t(14;22)(q32;q11) translocation involving IGH and IGL is rare in lymphomas. We report herein clinicopathological characteristics, response to treatment, and outcomes of a first splenic marginal zone lymphoma case with a t(14;22)(q32;q11) translocation involving IGH and IGL treated with rituximab, ibrutinib, and obinutuzumab. Studies of additional cases are needed to elucidate the potential role of the t(14;22) translocation in lymphomagenesis and prognostication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
- Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA. bal4006@med.cornell.edu.
- Department of Pathology and Laboratory Medicine, Weill Cornell Medical College of Cornell University, 1300 York Avenue, New York, NY, 10065, USA. bal4006@med.cornell.edu.
Zitieren
APA
Geyer, J. T., Ruan, J., Kluk, M. J., & Bao, L. (2025). t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumab. Annals of Hematology. https://doi.org/10.1007/s00277-025-06282-5
Vancouver
Geyer JT, Ruan J, Kluk MJ, Bao L. t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumab. Annals of Hematology. 2025. doi:10.1007/s00277-025-06282-5
BibTeX
@article{Geyer2025,
author = {Geyer, Julia T and Ruan, Jia and Kluk, Michael J and Bao, Liming},
title = {t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumab},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06282-5}
}
EUVIMED